SLU‑PP‑915
Pan-ERR (estrogen-related receptor α/β/γ) agonist "exercise-mimetic" research compound, the successor to SLU-PP-332 from the Burris lab (Saint Louis University). Key difference: ORALLY BIOAVAILABLE (the 332 is not) and more potent in vivo – it enhanced running/aerobic capacity to a similar extent as the 332 but at less than half the dose. RESEARCH-ONLY, no human trials.
Related comparisons
SLU-PP-332 vs SLU-PP-915WHAT IS SLU-PP-915?
Detailed overview
SLU-PP-915 is a pan-ERR (estrogen-related receptor, ERRα/β/γ) agonist and "exercise-mimetic" research compound developed by the Burris lab (Saint Louis University; "SLU" refers to Saint Louis University). It is the direct successor and improved version of SLU-PP-332. The main limitation of the 332 was poor oral absorption – and this is exactly the weakness the 915 was engineered to fix: SLU-PP-915 is ORALLY BIOAVAILABLE (SLU-PP-332 is not well absorbed orally), and it is more potent in vivo. Billon et al. (J Pharmacol Exp Ther, 2026, PMID 41421047) showed that the 915 enhanced running/aerobic capacity to a similar extent as SLU-PP-332 but at less than half the dose. Mechanism: ERRα/β/γ are orphan nuclear receptors that regulate genes for mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, and the Krebs (TCA) cycle, and are essential for skeletal-muscle adaptation to aerobic exercise. By activating ERR signalling, the 915 shifts gene expression toward fatty-acid oxidation and mitochondrial respiration, inducing an acute aerobic-exercise-like genetic program – hence the term "exercise mimetic." The compound is still a RESEARCH compound, not approved; it is available on the research-chemical market with label-claim and purity caveats. Doping relevance: SLU-PP-915 has been characterised analytically as having "doping potential" (Möller 2026 PMID 41588687), so athletes should treat ERR agonists as WADA-risky (metabolic-modulator-adjacent and likely prohibited/monitored).
Mechanism
Pan-ERR (ERRα/β/γ estrogen-related receptor) agonist – regulates genes for mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, Krebs cycle
Route
Orally bioavailable (its main advantage over SLU-PP-332, which is not well absorbed orally)
Half-life
Human PK NOT known (research-only, no human trials)
Onset
Acute aerobic-exercise-like gene-expression program; human onset NOT documented
Legal status
Not approved (research only). Available on the research-chemical market. WADA NOT explicitly listed, but due to its "doping potential" characterization, ERR agonists are WADA-risky as metabolic-modulator-adjacent compounds.
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Human side-effect profile is unknown: there is not a single human clinical trial, safety rests entirely on preclinical (animal/cell) data, so every item below is theoretical or preclinically derived.
- Research-chemical purity risk: label-claim discrepancy, underdosing or contaminated batches in market samples are realistic, so actual exposure and byproduct toxicity are unpredictable – often the single largest practical harm.
- As a mitochondrial/metabolic modulator it can theoretically cause a whole-body metabolic shift (toward fatty-acid oxidation, oxidative phosphorylation) whose human dose-response and overdose threshold are unknown.
- Hepatic and renal clearance pathways are uncharacterized in humans: liver and kidney metabolic load and any related enzyme or function changes cannot be predicted and therefore cannot be excluded.
- ERR receptors are central regulators of cardiac and skeletal muscle energy metabolism; the cardiac and muscle-tissue effects of sustained pharmacological activation are unstudied in humans, so cardiac safety remains an open question.
- Long-term safety is entirely unknown: there is no chronic-exposure human data, so cumulative or delayed risks (including effects on cell division/proliferation) cannot be assessed.
Contraindications · 6
- Pregnancy and breastfeeding: absolute contraindication – no teratogenicity data, the effect of metabolic/nuclear-receptor modulators on a developing fetus is unknown, the risk is unacceptable.
- Human consumption in general: the compound is research-only with no human trial, therefore human use is not recommended and is contraindicated outside an educational context.
- Pre-existing liver disease: relative contraindication – human hepatic clearance is unknown, accumulation and load cannot be estimated in an impaired liver.
- Pre-existing kidney disease: relative contraindication – human renal elimination is unknown, exposure may rise unpredictably with reduced kidney function.
- Competitive athletes: ERR agonists have been analytically characterized with "doping potential" (Möller 2026 PMID 41588687), so they should be avoided as metabolic-modulator-adjacent, WADA-risky substances – a competition ban is realistic.
- Known or suspected malignancy / proliferative condition: caution warranted – the human effect of nuclear-receptor activation and boosted cell energetics on proliferative processes is unstudied, therefore avoid.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
Billon C, Appourchaux K, Côté I, Burris TP
In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
Möller T, Krug O, Thevis M
Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications
de Souza-Lima J, Astrosa-Martin BD, Galaz-Rodríguez CA, Silva-Bernal JE et al.
Telegram
Have a question about SLU‑PP‑915?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.